Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000425

Lamivudine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C8H11N3O3S
Numéro CAS:
134678-17-4
Poids moléculaire :
229.26
Numéro MDL:
MFCD00869739
Code UNSPSC :
41116107
ID de substance PubChem :
329830949
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

lamivudine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

Clé InChI

JTEGQNOMFQHVDC-NKWVEPMBSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamivudine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1356858

Lamivudine Resolution Mixture B, United States Pharmacopeia (USP) Reference Standard

1356836

Lamivudine, United States Pharmacopeia (USP) Reference Standard

Y0000426

Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard

Y0000518

Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard

1356847

Lamivudine Resolution Mixture A, United States Pharmacopeia (USP) Reference Standard

1356869

Lamivudine Resolution Mixture C, United States Pharmacopeia (USP) Reference Standard

BP802

Lamivudine, British Pharmacopoeia (BP) Reference Standard

BP857

Lamivudine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP850

Zidovudine and Lamivudine impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR8938

Lamivudine (R)-Sulfoxide, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361

Conseils de prudence

P280

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Youwen Tan et al.
PloS one, 7(3), e32789-e32789 (2012-04-06)
Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy. This paper aims to assess the overall spontaneous incidence and
Zhongjie Shi et al.
Obstetrics and gynecology, 116(1), 147-159 (2010-06-23)
To evaluate efficacy of lamivudine in reducing in utero transmission of hepatitis B virus (HBV). A database was constructed from Medline, EMBASE, Cochrane Library, National Science Digital Library, China Biological Medicine Database, and through contact with experts in the field
Stephen Weller et al.
Journal of acquired immune deficiency syndromes (1999), 66(4), 393-398 (2014-05-07)
The integrase inhibitor dolutegravir and nucleoside analogues abacavir and lamivudine are once-daily treatment options for HIV. This study (NCT01622790) evaluated, first, the bioequivalence (BE) of a fixed-dose combination (FDC) tablet containing dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300
Kuo-Chih Tseng et al.
Antiviral therapy, 19(8), 755-764 (2014-03-04)
It is still inconclusive whether chronic hepatitis B (CHB) patients with persistently normal alanine aminotransferase (PNALT) should receive nucleoside/nucleotide analogues. This study is to evaluate the efficacy of entecavir in improving liver histology in CHB patients with PNALT. In this
N B Bhatt et al.
Antimicrobial agents and chemotherapy, 58(6), 3182-3190 (2014-03-26)
This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique